Blood and liver test changes in an early trial of the drug LP-184
Original title: Quantitative characterization of platelet count and alanine aminotransferase dynamics to inform personalized dosing in the first-in-human LP-184 trial.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This drug is in an early trial in people, mostly to check safety and dose.
The short version
Doctors tracked blood test changes in people taking a new drug, to help pick safer doses.
What was studied. This looked at data from the first trial of a drug called LP-184 in people. Researchers followed two blood tests over time: platelets, which help blood clot, and a liver enzyme called ALT.
What they found. Platelet counts dropped the most during the second cycle of treatment. People who started with a platelet count below 200 K/uL had a high risk of a serious drop. ALT levels usually peaked in the first cycle, and people with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary were more likely to have a bigger rise. A single dose above 40 mg was linked to more platelet and liver problems.
What this means, and what it doesn't
What it could mean: Blood tests taken before treatment may help a care team pick a safer dose. If your platelet count is low to start, your team may use a lower dose or check your blood more often.
What it doesn't mean: This does not mean LP-184 helps brain tumors. The study looked at side effects and dosing, not at whether the drug shrinks tumors. It comes from the first tests of the drug in people. The drug is not approved and is not part of regular care. This is not a promise of a cure.
Source: PubMed, August 12, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.